WHO Calls for Expressions of Interest in Developing Sabin-IPV

Safe and affordable inactivated polio vaccine for low-income countries.

One of the strategic priorities of the Global Polio Eradication Initiative is to enable low-income countries to produce Inactivated Polio Vaccine (IPV). To meet this objective,  the World Health Organization is working with academia, government and industry to develop an IPV  based on the non-infectious Sabin virus strain (sIPV). A range of manufacturers and research institutes have active programmes at various stages of development. The development and licensure of IPV produced from Sabin strains aims to reduce the number of manufacturing sites generating high volumes of high titre wild polioviruses for ”traditional” IPV production. Sabin polioviruses pose less of a threat in the event of an intentional or unintentional release from the production facility. This is a particular concern in low-income countries where the transmissibility of polioviruses is high.

Related


Related News

   03/03/2017
GPEI is seeking research proposals to accelerate polio eradication
   24/02/2017
Researchers have taken one step closer to poliovirus-free vaccine production
   17/11/2016
Research is delivering faster, cheaper and easier ways to administer the injectable inactivated polio vaccine to every last child
   08/11/2016
With SAGE recommending the use of fractional doses of the inactivated polio vaccine, a solution has been found to address global supply constraints
   03/11/2016
The Global Polio Eradication Initiative gets polio workers to the most vulnerable locations.
   14/03/2016
Safe and affordable inactivated polio vaccine for low-income countries